This is a Phase II, multi-center pilot study assessing the efficacy and safety of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligo-metastatic non-small cell lung cancer (NSCLC).

Inclusion Criteria:

• Histologically confirmed non-small cell lung cancer
• ≤3 metastatic organs and ≤5 metastatic lesions (supraclavicular and mediastinal lymph nodes are not classified as distant metastasis; other lymph node
• metastasis一group lymph node region will be classified as one metastatic lesion）
• Tissue biopsy prior to treatment
• ECOG performance score 0-1

Exclusion Criteria:

• EGFR mutation or ALK positive.
• Evidence on pulmonary interstitial disease or symptoms of active non-infectious pneumonia.
• Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.
• Previous treatment with antibody against pd -1, pd - L1, pd - L2, CD137 or CTLA-4 (including ipilimumab or any antibody or drug against T cell co-stimulation or checkpoint pathway).